Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Lu AF95245 in Healthy Young Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, young, non-smoking men with a body mass index (BMI) ≥18.5 kg/m2 and ≤30 kg/m2 at the Screening Visit.~Exclusion Criteria:~* The subject has any concurrent disorder that may affect the particular target or absorption, distribution, or elimination of the IMP.~Other in- and exclusion criteria may apply

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort A: single-ascending oral dose (Type: EXPERIMENTAL): Cohorts A1 to A6, single ascending dose, with 9 subjects in each cohort, sequential
- Cohort B: (fasting/fed conditions) (Type: EXPERIMENTAL): Groups B1, B2, and B3, with 4 subjects in each group and the groups will be running in parallel.~B1: fed-fasting-fasting condition (spiked dosage)~B2: fasting-fed-fasting condition (spiked dosage)~B3: fasting-fasting-fed condition

Based on this trial design, predict the completion outcome and termination type (if applicable).